American Century Companies’s Protagonist Therapeutics PTGX Stock Holding History

American Century Companies's PTGX Position: Q2 2026 in Review

American Century Companies increased its Protagonist Therapeutics (PTGX) stake by 11% in Q2 2026, buying an estimated $6.4M and bringing the position to 598,600 shares worth $73.4M. The position accounts for 0.03% of the portfolio, ranked #658.

American Century Companies first reported a position in PTGX in Q1 2018 and has held it in 18 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

• American Century Companies held 598,600 shares of Protagonist Therapeutics worth $73.4M as of Q2 2026.
• American Century Companies bought 61,280 Protagonist Therapeutics shares in Q2 2026, an estimated $6.4M.
• Protagonist Therapeutics made up 0.03% of American Century Companies's portfolio in Q2 2026, its #658 holding.
• American Century Companies first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 18 quarters since.
• 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.